Corxel Pharmaceuticals closed a $287 million Series D round to accelerate global development of CX‑11, a once‑daily oral GLP‑1 receptor agonist for obesity and type 2 diabetes. The round drew participation from RTW Investments, Hengdian Group Capital, SR One and others, positioning Corxel for expanded Phase II/III programs. CX‑11 showed roughly 9–10% weight loss at 16 weeks in earlier data and is now being positioned as a convenient oral alternative to injectable incretins. The financing underwrites clinical operations in the U.S. and China and supports regulatory and manufacturing scale‑up plans. The investment reflects intensified venture capital interest in oral incretin modalities after approvals and launches for competing oral and injectable agents. Corxel will need larger, longer trials and head‑to‑head evidence to prove commercial differentiation against established GLP‑1 brands. Market watchers view the raise as a signal that sizable private capital remains available for cardiometabolic programs with clear clinical endpoints and commercialization paths.